Vogel M, Feldman WB, Cowan Z, Rome BN, Chandra A, Kesselheim AS, Wouters OJ - JAMA Health Forum
- Research Publications
- Price, Value, and Access
Summary:
Among the top-selling small-molecule drugs and biologics eligible for Medicare drug price negotiation from 2012 to 2022, biologics generated substantially higher cumulative revenues than small-molecule drugs, totaling $4.9 billion more over 9 years and $7.9 billion more over 13 years. These findings suggest the longer exemption period for biologics from price negotiation is unecessary.
VIEW SOURCE
Recent Work from PORTAL
Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
- Research Publications
- Price, Value, and Access
Coverage and Costs for Medications After Medicare Price Negotiation
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
- Research Publications
- Price, Value, and Access
Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open
- Research Publications
- Price, Value, and Access
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.